Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Open Access
- 20 December 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0001308
Abstract
Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people 0.67. Primary analysis was done on the per-protocol population, including infection naïve participants only. 145 participants were enrolled and randomized, were mostly female (69.5%), of European origin (95%), with a mean age of 40.4 years (SD 7.9). At 28 days post second dose, the geometric mean titre (GMT) of anti-RBD IgG of the reduced dose regimen (1,705 BAU/mL) was not non-inferior to the full dose regimen (2,387 BAU/mL), with a GMR of 0.714 (two-sided 95% CI 0.540–0.944). No serious adverse events occurred. While non-inferiority of the reduced dose regimen was not demonstrated, the anti-RBD IgG titre was only moderately lower than that of the full dose regimen and, importantly, still markedly higher than the reported antibody response to the licensed adenoviral vector vaccines. These data suggest that reduced doses of the BNT162b2 mRNA vaccine may offer additional benefit as compared to the vaccines currently in use in most low and middle-income countries, warranting larger immunogenicity and effectiveness trials. Trial Registration: The trial is registered at ClinicalTrials.gov (NCT04852861).Keywords
All Related Versions
Funding Information
- Fonds Wetenschappelijk Onderzoek (G0G4220N)
This publication has 23 references indexed in Scilit:
- Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2021
- Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccinesBMJ Global Health, 2021
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccineVaccine, 2021
- Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccineAmerican Journal of Hematology, 2021
- Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trialThe Lancet, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- WHO position on the use of fractional doses – June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper – June 2013Vaccine, 2017
- Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle‐Free Device in CubaThe Journal of Infectious Diseases, 2010